1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Baseline characteristics of patients with acute ischemic stroke treated with IA thrombolysis
VariableAge <80 years (n = 81)Age ≥80 years (n = 33)
Mean age (range), years64 (25–79)86 (80–97)
Female, n (%)38 (47%)20 (61%)
Current tobacco use, n (%)19 (23%)7 (21%)
Hypertension, n (%)58 (72%)19 (58%)
Diabetes mellitus, n (%)13 (16%)4 (12%)
Hyperlipidemia, n (%)27 (33%)9 (27%)
Coronary artery disease, n (%)25 (31%)10 (30%)
Medium risk cardioembolic source, n (%)11 (14%)4 (12%)
High-risk cardioembolic source, n (%)39 (48%)20 (61%)
Prior stroke/TIA, n (%)17 (21%)*14 (42%)*
Peripheral vascular disease, n (%)2 (2%)3 (1%)
Antiplatelet therapy, n (%)31 (38%)10 (30%)
Warfarin therapy, n (%)11 (14%)7 (21%)
Weight, kg, mean ± SD75.8 ± 13.0*66.8 ± 10.8*
BP peak pretreatment, mm Hg, mean ± SD
    Systolic160 ± 30168 ± 38
    Diastolic86 ± 1892 ± 22
Glucose, mg/dL, mean ± SD149 ± 46146 ± 96
Platelets, ×103/μL, mean ± SD233 ± 83225 ± 68
Pretreatment NIHSS score, median (range)16 (2–38)17 (2–25)
Presence of hyperdense MCA sign, n (%)15 (19%)5 (15%)
Pathogenic mechanism
    Cardioembolic, n (%)25 (31%)12 (36%)
    Noncardioembolic, n (%)37 (46%)16 (48%)
    Undetermined, n (%)19 (23%)5 (16%)
Location: anterior circulation, n (%)67 (83%)29 (88%)
Target vessel localization, n (%)
    Extracranial internal carotid artery12 (15%)2 (6%)
    Intracranial internal carotid artery10 (12%)5 (15%)
    Both intracranial and extracranial internal carotid artery1 (1%)0 (0%)
    Middle cerebral artery44 (54%)17 (52%)
    Anterior cerebral artery4 (5%)2 (6%)
    Posterior cerebral artery5 (5%)1 (3%)
    Vertebrobasilar11 (14%)4 (12%)
  • Note:—IA indicates intra-arterial; TIA, transient ischemic attack; BP, blood pressure; NIHSS, National Institutes of Health Stroke Scale; MCA, middle cerebral artery.
  • * P ≤ 0.05